Robert Roscigno Email & Phone Number

Seasoned Executive with a unique combination of scientific and business expertise in the pharmaceutical industry. Analytical manager leveraging diverse product development/commercialization strategies for pulmonary and cardiovascular drugs. Successfully launched subsidiary of world-renowned biotechnology company,taking its most advanced product from preclinical development through Phase III.“Robert was one of the principal scientific developers of Remodulin, and has also been the key individual responsible for its commercial acceptance in the United States and overseas.”Martine Rothblatt, Chairman/CEO, United Therapeutics.Overcame difficulty with product’s significant side effects, label issues, and negative KOL opinionSurpassed $100M in worldwide sales by increasing physician usage, patient retention, and community awareness.Amplified revenue $88M in 4 years (40% annually), exceeding goals by 20%.Increased prescriber base 4-fold and decreased patient dropouts 20% by developing conference-based education programs and treatment management initiatives.Directed $10M R&D budget as founding member of startup and $3M budget for commercial developmentSaved $2M by negotiating with Medicare to retroactively reimburse for all patients in clinical studies.Reduced overhead costs $3M over 2 years by outsourcing multiple functions.Achieved 88% profit margin, resulting in 30% average growth – one of the highest rates for a US biotech.Ph.D., Microbiology and Immunology, Duke University ▪ BS, Biology, Trinity CollegeHolder of 5 US Patents ▪ Co-Author of 9 Published Articles

Listed skills include Clinical Development, Clinical Trials, Biotechnology, Pharmaceutical Industry, and 8 others.